Lumenis targets ophthalmology with four new lasers at AAO meeting
NOVEMBER 9, 2008 -- Lumenis Ltd. (Yokneam, Israel) has introduced four new ophthalmic lasers and delivery devices at the American Academy of Ophthalmology (AAO) annual meeting, which began Friday. The company is demonstrating two units that combine technologies and applications for flexibility and performance; a powerful dual-port photocoagulator; and a family of endo photocoagulation laser probes for retinal applications.
NOVEMBER 9, 2008 -- Lumenis Ltd. (Yokneam, Israel) has introduced four new ophthalmic lasers and delivery devices at the American Academy of Ophthalmology (AAO) annual meeting, which began Friday (November 7-12, Atlanta, GA). The company is demonstrating two Selecta lasers: a small-footprint unit that enables retinal, cataract and advanced glaucoma therapies, and an anterior-segment laser that combine YAG and SLT technologies; plus a powerful dual-port photocoagulator; and a family of endo photocoagulation laser probes for retinal applications.
The first product, Lumenis's Selecta Trio, offers retinal, cataract and advanced glaucoma therapies in a single, compact platform. It features an integrated design, enhanced optics, advanced laser cavity for high performance.
The Selecta Duet anterior-segment laser combines the advantages of YAG photodisruption capabilities along with Lumenis's Selective Laser Trabeculoplasty (SLT) technology. Lumenis says it is the only upgradeable SLT and YAG combination laser currently available, and thus gives customers the option to adding photocoagulation capability at any point. Like the Selectra Trio, it promises performance through its integrated design, enhanced optics, advanced laser cavity.
The Novus Spectra Dual-Port photocoagulator owes its power and reliability to proprietary advancements in diode-pumped solid-state (DPSS) technology. DPSS drives 2.5 W of power from the compact Novus Spectra system, while an active resonator temperature control ensures stable beam output and system reliability. The Novus Spectra is compatible with a wide array of delivery devices.
Finally, the LumeProbe Endo Photocoagulation Laser Probes target the retina specialist. "Based on over 25 years of laser probes manufacturing expertise, the LumeProbe product family was designed to deliver laser energy in the safest and most efficient manner, guaranteeing optimal clinical outcome for all relevant viteroretinal indications," said Gideon (Gidi) Sturlesi, corporate VP and acting general manager of Lumenis Vision, the company's ophthalmic business unit.
Lumenis is a developer, manufacturer and marketer of laser, light-based and radiofrequency devices for ophthalmic, surgical and aesthetic applications. The company says that in 1970, it was the first to introduce a laser into the ophthalmic field and has followed with other milestones, including the first laser photocoagulator, laser indirect ophthalmoscope, multicolor photocoagulator, photodynamic therapy laser, its Selective Laser Trabeculoplasty (SLT) system and solid state multicolor laser.